DexCom (NASDAQ:DXCM) had its target price upped by UBS Group from $135.00 to $140.00 in a research note issued to investors on Tuesday morning, www.benzinga.com reports. The brokerage currently has a neutral rating on the medical device company’s stock.
Several other equities analysts have also weighed in on the company. Morgan Stanley cut their target price on DexCom from $150.00 to $135.00 and set an equal weight rating on the stock in a research note on Wednesday, January 2nd. BidaskClub raised DexCom from a hold rating to a buy rating in a research note on Friday, December 28th. Oppenheimer set a $150.00 target price on DexCom and gave the company a buy rating in a research note on Thursday, December 6th. Jefferies Financial Group raised their price target on DexCom to $148.00 and gave the stock a buy rating in a research report on Wednesday, November 7th. Finally, Stephens raised their price target on DexCom from $170.00 to $160.00 and gave the stock an overweight rating in a research report on Wednesday, November 7th. Seven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. DexCom has an average rating of Buy and a consensus target price of $137.06.
NASDAQ:DXCM traded down $1.07 during mid-day trading on Tuesday, hitting $140.83. The company had a trading volume of 22,456 shares, compared to its average volume of 1,049,744. DexCom has a fifty-two week low of $52.92 and a fifty-two week high of $152.14. The company has a current ratio of 4.71, a quick ratio of 4.43 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $12.33 billion, a price-to-earnings ratio of -242.91 and a beta of 0.63.
DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.29. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The firm had revenue of $266.70 million for the quarter, compared to analyst estimates of $242.72 million. The company’s revenue was up 44.5% compared to the same quarter last year. Sell-side analysts predict that DexCom will post -0.13 earnings per share for the current year.
In related news, SVP Heather S. Ace sold 4,258 shares of the stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $147.32, for a total transaction of $627,288.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Steven Robert Pacelli sold 3,114 shares of the stock in a transaction dated Tuesday, October 23rd. The stock was sold at an average price of $128.85, for a total value of $401,238.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,995 shares of company stock valued at $7,810,555. 1.80% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. Waddell & Reed Financial Inc. grew its stake in DexCom by 164.8% in the second quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after purchasing an additional 354,331 shares in the last quarter. Swiss National Bank grew its stake in DexCom by 1.0% in the third quarter. Swiss National Bank now owns 153,600 shares of the medical device company’s stock valued at $21,971,000 after purchasing an additional 1,500 shares in the last quarter. BlackRock Inc. grew its stake in DexCom by 5.9% in the second quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after purchasing an additional 228,933 shares in the last quarter. Macquarie Group Ltd. grew its stake in DexCom by 14.4% in the second quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock valued at $22,448,000 after purchasing an additional 29,825 shares in the last quarter. Finally, Northern Trust Corp grew its stake in DexCom by 4.3% in the second quarter. Northern Trust Corp now owns 451,647 shares of the medical device company’s stock valued at $42,896,000 after purchasing an additional 18,631 shares in the last quarter. Hedge funds and other institutional investors own 98.79% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.